Clinical Pharmacokinetics

, Volume 8, Issue 6, pp 530–540

Pharmacokinetic Study of Zimelidine Using a New GLC Method

  • Gilles Caillé
  • Edouard Kouassi
  • Claude de Montigny
Original Research Article

Summary

A specific, sensitive, rapid and reproducible analytical method for zimelidine [3-(4-bromophenyl)-N,N-dimethyl-3(3-pyridyl)allylamine] and its biologically active demethylated metabolite, norzimelidine, in human plasma was developed using gas-liquid chromatography (GLC) with loxapine as the internal standard. A good separation of zimelidine and norzimelidine was obtained following derivatisation of norzimelidine with heptafluorobutyric anhydride, the retention times being 6.16 and 10.35 minutes, respectively. The sensitivity of the method is 5 ng/ml for zimelidine and norzimelidine.

Plasma concentrations of zimelidine and norzimelidine were determined in 10 healthy volunteers following the administration of a single oral dose of 100mg zimelidine. Zimelidine was rapidly absorbed, giving a mean peak plasma concentration of 103.9 ± 34.8 ng/ml. The mean plasma elimination half-life was 8.4 ± 2.0 hours for zimelidine and 19.4 ± 3.6 hours for norzimelidine. After long term administration of zimelidine (100mg bid for the first week, 100mg tid for the second week and 100mg am and 200mg pm for the third and fourth weeks) to 2 depressed patients, plasma concentrations of norzimelidine were 2 to 4 times higher than those of zimelidine.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Åberg, A.: Controlled cross-over study of 5-HT uptake inhibiting and an NA uptake inhibiting antidepressant. Acta Psychiairica Scandinavica 63: 244–255 (1981).CrossRefGoogle Scholar
  2. Åberg, A. and Holmberg, G.: Preliminary clinical test of zimelidine, a new 5-HT uptake inhibitor. Acta Psychiatrica Scandinavica 59: 45–58 (1979).PubMedCrossRefGoogle Scholar
  3. Aberg-Wistedt, A.; Jostell, K.-G.; Ross, S.B. and Westerlund, D.: Effects of zimelidine and desipramine and serotonin and noradrenaline uptake mechanisms in relation to plasma concentrations and to therapeutic effects during treatment of depression. Psychopharmacology 74: 297–305 (1981).PubMedCrossRefGoogle Scholar
  4. Alexanderson, B.; Price-Evans, D.A. and Sjöqvist, F.: Steady-state plasma levels of nortriptyline in twins: Influence of genetic factors and drug therapy. British Medical Journal 4: 764–768 (1969).PubMedCrossRefGoogle Scholar
  5. Alexanderson, B. and Sjöqvist, F.: Inter-individual differences in the pharmacokinelics of monomethylated tricyclic anti-depressants: Role of genetic and environmental factors and clinical importance. Annals of the New York Academy of Science 179: 739–751 (1971).CrossRefGoogle Scholar
  6. Asberg, M.: Cronholm, B.; Sjöqvist, F. and Tuck, D.: Relationship between plasma level and therapeutic effect of nortriptyline. British Medical Journal 3: 331–334 (1971).PubMedCrossRefGoogle Scholar
  7. Bcrtilsson, L.; Tuck, J.R. and Siwers, B.: Biochemical effects of zimelidine in man. European Journal of Clinical Pharmacology 18: 483–487 (1980).CrossRefGoogle Scholar
  8. Borg, K.-O.; Johnson, G.; Jordö, L.; Lundborg, P.; Rönn, O. and Welin-Fogelberg, I.: Interaction studies between three anti-depressant drugs (zimelidine, imipramine and chlorimipramine) and noradrenaline in healthy volunteers and some pharmacokinetics of the drugs studied. Acta Pharmacologica et Toxicologica 45: 198–205 (1979).PubMedCrossRefGoogle Scholar
  9. Brown, D.; Scott, D.H.T.; Scott, D.B.; Meyer, M.; Westerlund, D. and Lundstrom, J.: Pharmacokinetics of zimelidine. European Journal of Clinical Pharmacology 17: 111–116 (1980).PubMedCrossRefGoogle Scholar
  10. Calil, H.M.; Jostell, K.G.; Cowdry, R.W. and Potter, W.Z.: Zimelidine and norzimelidine protein binding measured by equilibrium dialysis and cerebrospinal fluid. Clinical Pharmacology and Therapeutics 31: 522–527 (1982a).PubMedCrossRefGoogle Scholar
  11. Coppen, A.; Rama Rao, V.A. and Wood, K.: Inhibition of 5-hydroxytryptamine reuptake by amitriptyline and zimelidine and its relationship to their therapeutic action. Psychopharmacology 63: 125–129 (1979a).PubMedCrossRefGoogle Scholar
  12. Coppen, A.; Ramao Rao, V.A.; Swade, C. and Wood, K.: Zimelidine: A therapeutic and pharmacokinetic study in depression. Psychopharmacology 63: 199–202 (1979b).PubMedCrossRefGoogle Scholar
  13. de Montigny, C.: Electroconvulsive shock treatment increases responsiveness of forebrain neurons to serotonin: A microiontophoretic study in the rat. Neuroscience Abstracts 6: 152–27 (1980).Google Scholar
  14. de Montigny, C, and Aghajanian, G.K.: Tricyclic antidepressants: Long-term treatment increases responsivity of rat forebrain neurons to serotonin. Science 202; 1303–1306 (1978).PubMedCrossRefGoogle Scholar
  15. de Montigny, C.; Blier, P.: Caillé, G. and Kouassi, E.: Pre- and postsynaptic effects of zimelidine and norzimelidine on the serotoninergic system: Single cell studies in the rat. Acta Psychiatrica Scandinavica 63: 79–80 (1981a).CrossRefGoogle Scholar
  16. de Montigny, C.; Grunberg, F.; Mayer, A. and Deschesnes, J.P.: Lithium induces rapid relief of depression in tricyclic anti-depressant drug non-responders. British Journal of Psychiatry 138: 252 (1981b).PubMedCrossRefGoogle Scholar
  17. Emanuelsson, B. and Moore, R.G.: Quantitation of zimelidine and norzimelidine in plasma using high-performance liquid chromatography. Journal of Chromatograph, Biomedical Applications 146: 113–119 (1978).CrossRefGoogle Scholar
  18. Gallager, D.W. and Bunney, W.E. Jr: Failure of chronic lithium treatment to block tricyclic antidepressant-induced 5-HT su-persensitivity. Naunyn-Schmiedeberg’s Archives of Pharmacology 307: 129–133 (1979).PubMedCrossRefGoogle Scholar
  19. Gibaldi, M. and Perrier, D.: Pharmacokinetic, Vol. 1 (Marcel Dckke, New York. 1975).Google Scholar
  20. Grahame-Smith, D.G. and Green, A.R.: The role of brain, 5-hy-droxytryptamine in the hyperactivity produced in rats by lithium and monoamine oxidase inhibitors. British Journal of Pharmacology 52: 19–26 (1974).PubMedCrossRefGoogle Scholar
  21. Gram, L.F. and Christiansen, J.: First pass metabolism of imipramine in man. Clinical Pharmacology and Therapeutics 17: 555–563 (1975).PubMedGoogle Scholar
  22. Gupta, R. and Molnar, G.: Measurement of therapeutic concentrations of tricyclic antidepressants in serum. Drug Metabolism Reviews 9: 79–97 (1979).PubMedCrossRefGoogle Scholar
  23. Hansen, L.B.: Thomsen, I.S.; Vestergard, P.; Larsen, N.E. and Hvidberg, E.F.: Plasma levels of zimelidine and norzimelidine in endogenous depression. Psychopharmacology 69: 157–160 (1980).PubMedCrossRefGoogle Scholar
  24. Högberg, K. and Ulff, B.: Simultaneous GLC determination of zimelidine and norzimelidine synthesis of secondary amines as closely related internal standards. Acta Pharmaceutica Suecica 16: 299–308 (1979).PubMedGoogle Scholar
  25. Larsen, N.-E. and Marinelli, K.: Determination of zimelidine and ils demethylated metabolite in human plasma by gas chromatography. Journal of Chromatography 156: 335–339 (1978).PubMedCrossRefGoogle Scholar
  26. Mellström, B.; Bertilsson, L.; Traskman, L.; Rollins, D.; Åsberg, M. and Sjöqvist, F.: Intraindividual similarity in the metabolism of amitriptyline and chlorimipramine in depressed patients. Pharmacology 19: 282–287 (1979).PubMedCrossRefGoogle Scholar
  27. Montgomery, S.A.; Rani, S.J.; McAnley, R.; Roy, D. and Montgomery, D.B.: The antidepressant efficacy of zimelidine and maprotiline. Acta Psychiatrica Scandinavica 63: 219–235 (1981).CrossRefGoogle Scholar
  28. Nagy, A. and Johansson, R.: The demethylation of imipramine and clomipramine as apparent from their plasma kinetics. Psychopharmacology 54: 125–131 (1977).PubMedCrossRefGoogle Scholar
  29. Ross, S.B.; Ogren, S. and Renyi, A.L.: (Z)-dimethylamino-l-(4-bromophenyl)-1-(3-pyridyl) propene (H102/09), a new selective inhibitor of the neuronal 5-hydroxytryptamine uptake. Acta Pharmacologica et Toxicologica 39: 152–166 (1976).PubMedCrossRefGoogle Scholar
  30. Ross, S.B. and Renyi, A.L.: Inhibition of the neuronal uptake of hydroxytryptamine + noradrenaline in rat brain by (Z) — and (E)-3-(4-Bromophenyl)- N, N-Dimethyl-3-(3-Pyridyl) allylamines and their secondary analogues. Neuropharmacology 16: 57–63 (1977).PubMedCrossRefGoogle Scholar
  31. Shopsin, B.; Gershon, S.; Goldstein, M.; Friedman, E. and Wilk, S.: Use of synthesis inhibitors in defining a role for biogenic amines during imipramine treatment in depressed patients. Psychopharmacology Communications 1: 239–249 (1975).PubMedGoogle Scholar
  32. Spitzer, R.L.; Endicott, J. and Robins. E.: Research diagnostic criteria. Archives of General Psychiatry 35: 773–782 (1978).PubMedCrossRefGoogle Scholar
  33. Walter, C.J.S.: Clinical significance of plasma imipramine levels. Proceedings of the Royal Society of Medicine 64: 282–285 (1971).PubMedGoogle Scholar
  34. Wang, R.Y. and Aghajanian, G.K.: Enhanced sensitivity of amygdaloid neurons to serotonin and nerepinephrine after chronic antidepressant treatment. Communications in Psychopharmacology 4: 83–90 (1980).PubMedGoogle Scholar
  35. Westerlund, D. and Erixon, E.: Reversed-phase chromatography of zimelidine and similar dibasic amines. I. Analysis in biological material. Journal of Chromatography 185: 593–603 (1979).PubMedCrossRefGoogle Scholar
  36. Ziegler, V.E.; Biggs, J.T.; Rosen, J.H.; Meyer, D.A. and Preskorn, S.H.: Imipramine and desipramine plasma levels: Relationship to dosage schedule and sampling time. Journal of Clinical Psychiatry 39: 660–663 (1978).PubMedGoogle Scholar

Copyright information

© ADIS Press Australasia Pty Ltd. 1983

Authors and Affiliations

  • Gilles Caillé
    • 1
  • Edouard Kouassi
    • 1
  • Claude de Montigny
    • 1
  1. 1.Department of Pharmacology and Neuroscience Research Center, Faculty of MedicineUniversity of MontrealMontrealCanada

Personalised recommendations